SLS$1.49
$1.56
Chart
Performance
Key Stats
AI SLS Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
NeutralSELLAS Life Sciences Group is a clinical-stage biopharmaceutical company focused on cancer therapeutics. While its lead candidates, galinpepimut-S and SLS009, show potential, the company is pre-revenue, highly speculative, and has a history of negative earnings. Technical indicators are mixed. Investors should be aware of the significant risks and potential for high volatility.
Thematic
SELLAS Life Sciences Group operates in the oncology and immunotherapy space, which benefits from ongoing innovation and increasing healthcare spending. The collaboration with Merck for galinpepimut-S is a positive thematic driver, indicating potential validation by a major pharmaceutical player. However, the success of these therapies is heavily dependent on clinical trial outcomes and regulatory approval.
Fundamental
SELLAS Life Sciences Group is a pre-revenue company with no current revenue and consistent net losses. While it has cash equivalents to fund operations, its free cash flow has been significantly negative, indicating substantial cash burn. The debt-to-equity ratio is high due to limited equity, and the lack of profitability and revenue makes traditional valuation multiples less meaningful.
Technical
The stock is trading at low price levels, below its 50-day and 200-day moving averages, indicating a bearish trend. While some oscillators suggest a potential for short-term bounce (e.g., Stochastic %K, CCI, Stochastic RSI Fast), the overall technical picture is weak, with most moving averages signaling 'Sell'.
| Factor | Score |
|---|---|
| Oncology Therapeutics Market | 70 |
| Immunotherapy Advancements | 75 |
| Clinical Trial Success Dependence | 40 |
| Biotech Funding Environment | 30 |
| Strategic Partnerships | 65 |
| Factor | Score |
|---|---|
| Revenue | 0 |
| Profitability | 5 |
| Growth | 0 |
| Balance Sheet Health | 30 |
| Balance Sheet Health | 10 |
| Cash Flow | 10 |
| Valuation | 5 |
| Factor | Score |
|---|---|
| Trend Analysis | 20 |
| Momentum | 40 |
| Momentum | 70 |
| Volume | 50 |
| Support & Resistance | 45 |
| Short-term Oscillators | 50 |
AI Investing Checklist
Powered by LiveAIBullish Points (7)
Positive Medium to Long-Term Performance
The stock has shown strong performance over the past 6 months (27.66%) and year-to-date (68.22%), indicating positive investor sentiment and potential for continued growth.
Negative P/E Ratio (Potential for Future Earnings)
The trailing P/E ratio is negative (-9.1 TTM), which can be indicative of a company investing heavily in growth or experiencing a temporary downturn, potentially leading to higher future earnings if successful.
Bearish Points (8)
Consistent Net Losses
The company has consistently reported net losses across all reported periods (TTM, 2024, 2023, 2022, 2021), indicating a lack of profitability and a negative EPS trend.
Zero Revenue and High P/S Ratio (Historically)
The company has reported zero revenue in recent periods, leading to historically high or undefined Price-to-Sales (P/S) ratios (e.g., 179.6 in 2022), indicating a business model not yet generating sales.
Calendar
November 2019
8
Next Dividend Date
August 2025
15
Next Earnings Date
H: $-0.06
A: $-0.08
L: $-0.10
Profile
SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.
Seasonals
Price Target
5.83 USD
The 39 analysts offering 1 year price forecasts for SLS have a max estimate of 7.50 and a min estimate of 4.00.
Debt Level and Coverage
Financial Position Analysis
Ownership
Capital Structure
Valuation - Summary
Valuation - Ratios
Revenue to Profit Conversion
Balance Sheet
Cash Flow
Related Companies
Powered by LiveAIWeight: 90
Large biopharmaceutical company with a significant oncology portfolio, including immunotherapies and bispecific antibodies, offering broad competitive and partnership potential.
Weight: 88
Major player in immuno-oncology with blockbuster drugs like Opdivo and Yervoy, and a strong cell therapy presence, making it a direct competitor and potential M&A partner in oncology.
Weight: 87
Developer of Keytruda, a leading immunotherapy, positioning it as a significant competitor and benchmark in the broader cancer immunotherapy landscape.
Weight: 85
Established pharmaceutical company with a substantial oncology division, encompassing targeted therapies, biologics, and a growing presence in cancer immunotherapies.